KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.Am J TherPMID 37713687无 PMCID2023 Sep0.98未发现恶性肿瘤人群证据。待处理
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.Asia Pac J Ophthalmol (Phila)PMID 37851562无 PMCID2023 Sep0.98未发现恶性肿瘤人群证据。待处理
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.Lancet RheumatolPMID 38251497无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.Lancet RheumatolPMID 38251498无 PMCID2023-Sep0.98未发现恶性肿瘤人群证据。待处理
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.N Engl J MedPMID 37646676无 PMCID2023-Aug-310.98未发现恶性肿瘤人群证据。待处理
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.J Infect DisPMID 37650231PMC104693412023-Aug-310.98未发现恶性肿瘤人群证据。待处理
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.Breast Cancer ResPMID 37653397PMC104698772023-Aug-310.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18-60 and 60+ Age Cohorts.VirusesPMID 37766235PMC105379142023-Aug-290.98未发现恶性肿瘤人群证据。待处理
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 37385278无 PMCID2023-Aug-260.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.LancetPMID 37385279无 PMCID2023-Aug-260.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).Mod RheumatolPMID 36197757无 PMCID2023-Aug-250.45The study is a randomized Phase II/III trial with a drug intervention, but it is for rheumatoid arthritis (non-oncology) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS).待处理
Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).Mod RheumatolPMID 36201360无 PMCID2023-Aug-250.95The trial is a Phase III, randomized, drug intervention study in humans with primary efficacy and safety endpoints, but it is not oncology. Therefore, it does not meet the primary requirement of being a human malignant-neoplasm trial.待处理
Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.Medicine (Baltimore)PMID 37653768PMC104706982023-Aug-250.98未发现恶性肿瘤人群证据。待处理
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.N Engl J MedPMID 37486775PMC105645562023-Aug-240.98未发现恶性肿瘤人群证据。待处理
The Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of discontinuation versus continuation of growth hormone treatment in pubertal children with isolated GHD-a non-inferiority Randomised Controlled Trial (RCT).TrialsPMID 37605233PMC104408732023-Aug-210.98未发现恶性肿瘤人群证据。待处理
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.LancetPMID 37385275无 PMCID2023-Aug-190.98未发现恶性肿瘤人群证据。待处理
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.BMC CancerPMID 37596517PMC104366482023-Aug-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.BMJ OpenPMID 37597868PMC104410512023-Aug-180.98未发现恶性肿瘤人群证据。待处理
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.N Engl J MedPMID 37272516PMC114457632023-Aug-170.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.Gynecol EndocrinolPMID 37634528无 PMCID2023-Aug-170.98未发现恶性肿瘤人群证据。待处理
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.Arthritis Res TherPMID 37587493PMC104285252023-Aug-160.95The study is a randomized, phase 3b trial with a drug intervention (guselkumab) and reports original results. However, it is not an oncology study (psoriatic arthritis) and does not include a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as a primary or key secondary outcome; the primary focus is on serum biomarkers and clinical response metrics like ACR20.待处理
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.Int J CancerPMID 36971103无 PMCID2023-Aug-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials).Am J Respir Crit Care MedPMID 37364283PMC104490672023-Aug-150.98未发现恶性肿瘤人群证据。待处理
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.Signal Transduct Target TherPMID 37574511PMC104237172023-Aug-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase II dose evaluation pilot feasibility randomized controlled trial of cholecalciferol in critically ill children with vitamin D deficiency (VITdAL-PICU study).BMC PediatrPMID 37580663PMC104243612023-Aug-140.98未发现恶性肿瘤人群证据。待处理
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.LancetPMID 37423231无 PMCID2023-Aug-120.98未发现恶性肿瘤人群证据。待处理
Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan.Orphanet J Rare DisPMID 37568154PMC104165302023-Aug-110.98未发现恶性肿瘤人群证据。待处理
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.N Engl J MedPMID 37272513PMC110749232023-Aug-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.Sci RepPMID 37558720PMC104125882023-Aug-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.BMC CancerPMID 37559004PMC104137072023-Aug-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data.BMJ OpenPMID 37550019PMC104073592023-Aug-070.98未发现恶性肿瘤人群证据。待处理
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.LancetPMID 37423228无 PMCID2023-Aug-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.J Transl MedPMID 37543586PMC104038992023-Aug-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).OncologistPMID 37284847PMC104001422023-Aug-030.80The trial is a Phase III randomized oncology trial in humans, but its primary efficacy outcome is the prevention of chemotherapy-induced nausea and vomiting, which does not constitute a survival, progression, recurrence, or time-to-event efficacy endpoint as defined by the adjudication criteria for Kaplan-Meier digitization.待处理
Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.Rheumatology (Oxford)PMID 36534825PMC103934292023-Aug-010.98未发现恶性肿瘤人群证据。待处理
A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas.J NeurosurgPMID 36670529无 PMCID2023-Aug-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial.Clin Orthop Relat ResPMID 36961220PMC103445432023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.J Clin OncolPMID 36977289无 PMCID2023-Aug-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.Int J CancerPMID 37141294无 PMCID2023-Aug-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of Placebo Patients From 3 Randomized Phase III Studies.Clin J PainPMID 37166199PMC103535342023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.Clin Cancer ResPMID 37184934无 PMCID2023-Aug-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immunogenicity and Safety of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T, bOPV, and IPV Vaccines Administered at 2, 4, 6 Months of Age Concomitantly With Rotavirus and Pneumococcal Conjugate Vaccines in Healthy Infants in Thailand.Pediatr Infect Dis JPMID 37257121PMC103486502023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.J Clin OncolPMID 37290035PMC104195792023-Aug-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.HepatologyPMID 37386786PMC103444372023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.JAMA Netw OpenPMID 37526936PMC103945702023-Aug-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw OpenPMID 37526937PMC103945822023-Aug-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.Hum Vaccin ImmunotherPMID 37549923PMC104086932023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Acute Kidney Injury Defined by Fluid-Corrected Creatinine in Premature Neonates: A Secondary Analysis of the PENUT Randomized Clinical Trial.JAMA Netw OpenPMID 37561461PMC104159632023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.Hum Vaccin ImmunotherPMID 37587615PMC104388522023-Aug-010.98未发现恶性肿瘤人群证据。待处理
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.Diabetes Obes MetabPMID 37232058无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理